Policy | August 03, 2022
PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Subscribe To Our Newsletter & Stay Updated
